Advances in coronary stent technology - active drug-loaded stent surfaces for prevention of restenosis and improvement of biocompatibility

Current Pharmaceutical Biotechnology

Volumn 14, Issue 1, 2013, Pages 76-90

  Sternberg, Katrin ^a   Grabow, Niels ^a   Petersen, Svea ^a   Weitschies, Werner ^b   Harder, Claus ^c   Ince, Hüseyin ^a   Kroemer, Heyo K ^b   Schmitz, Klaus Peter ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c Biotronik SE and Co KG Technologie und Servicezentrum   (Germany)

Author keywords

Absorbable stent; Drug relelease; Drug eluting stent; In situ endothelialization; Stent; Stent coating

Indexed keywords

CD34 ANTIGEN; EVEROLIMUS; GRANULOCYTE COLONY STIMULATING FACTOR; NITINOL; PACLITAXEL; PIMECROLIMUS; POLYLACTIDE; POLYMER; RAPAMYCIN; STROMAL CELL DERIVED FACTOR 1; UMIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ZOTAROLIMUS;

BARE METAL STENT; BIOCOMPATIBILITY; CONTROLLED DRUG RELEASE; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ENDOTHELIAL PROGENITOR CELL; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER;

ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROSTHESIS DESIGN;

EID: 84872537353     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920113804805377     Document Type: Review

References (144)

1. Gruntzig, A.; Senning, A.; Siegenthaler, W. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med., 1979, 301, 61.
2. Dotter, C. Transluminally-placed coilspring endarterial tube grafts. Long-term patency in canine popliteal artery. Invest. Radiol., 1969, 4, 329.
3. Hanawa, T. Materials for metallic stents. J. Artif. Organs, 2009, 12, 73.
4. Sigwart, U.; Puel, J.; Mirkovitch, V.; Joffre, F.; Kappenberger, L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med., 1987, 316, 701.
5. Palmaz, J.; Kopp, D.; Hayashi, H.; Schatz, R.; Hunter, G.; Tio, F.; Garcia, O.; Alvarado, R.; Rees, C.; Thomas, S. Normal and stenotic renal arteries: experimental balloon-expandable intraluminal stenting. Radiology, 1987, 164, 705.
6. Serruys, P.; de Jaegere, P.; Kiemeneij, F.; Macaya, C.; Rutsch, W.; Heyndrickx, G.; Emanuelsson, H.; Marco, J.; Legrand, V.; Materne, P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med., 1994, 331, 489.
7. Fischman, D.; Leon, M.; Baim, D.; Schatz, R.; Savage, M.; Penn, I.; Detre, K.; Veltri, L.; Ricci, D.; Nobuyoshi, M. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med., 1994, 331, 496.
8. Holmes, D.R., J.; Hirshfeld, J., J.; Faxon, D.; Vlietstra, R.; Jacobs, A.; King, S.B. ACC expert consensus document on coronary artery stents. J. Am. Coll. Cardiol., 1998, 32, 1471.
9. Dahm, J.; Willems, T.; Wolpers, H.; Nordbeck, H.; Becker, J.; Ruppert, J. Clinical investigation into the observation that silicon carbide coating on cobalt chromium stents leads to early differentiating functional endothelial layer, increased safety and DES-like recurrent stenosis rates: results of the PRO-Heal Registry (PROKinetic enhancing rapid in-stent endothelialisation). EuroIntervention, 2009, 502.
10. Kukreja, N.; Onuma, Y.; Daemen, J.; Serruys, P. Perspective: The future of drug-eluting stents. Pharm. Res. 2008, 57, 171.
11. Grube, E.; Gerckens, U.; Müller, R.; Büllesfeld, L. Drug eluting stents: initial experiences. Z. Kardiol., 2002, 91(Suppl 3), 44.
12. Burt, H.; Hunter, W. Drug-eluting stents: a multidisciplinary success story. Adv. Drug Delivery Rev., 2006, 58, 350.
13. Machan, L. Clinical experience and applications of drug-eluting stents in the noncoronary vasculature, bile duct and esophagus. Adv. Drug Delivery Rev., 2006, 58, 447.
14. Acharya, G.; Park, K. Mechanisms of controlled drug release from drug-eluting stents. Adv. Drug Delivery Rev. 2006, 58, 387.
15. Regar, E.; Sianos, G.; Serruys, P. Stent development and local drug delivery. Br. Med. Bull., 2001, 59, 227.
16. Morice, M.; Serruys, P.; Sousa, J.; Fajadet, J.; Ban, H.E.; Perin, M.; Colombo, A.; Schuler, G.; Barragan, P.; Guagliumi, G.; Molnàr, F.; Falotico, R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med., 2002, 346, 1773.
17. Finn, A.; Nakazawa, G.; Joner, M.; Kolodgie, F.; Mont, E.; Gold, H.; Virmani, R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 1500.
18. Ranade, S.; Miller, K.; Richard, R.; Chan, A.; Allen, M.; Helmus, M. Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent. J. Biomed. Mater. Res. A, 2004, 71, 625.
19. Colombo, A.; Drzewiecki, J.; Banning, A.; Grube, E.; Hauptmann, K.; Silber, S.; Dudek, D.; Fort, S.; Schiele, F.; Zmudka, K.; Guagliumi, G.; Russell, M. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxeleluting stents for coronary artery lesions. Circulation, 2003, 108, 788.
20. Farb, A.; Burke, A.; Kolodgie, F.; Virmani, R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation, 2003, 108, 1701.
21. Joner, M.; Finn, A.; Farb, A.; Mont, E.; Kolodgie, F.; Ladich, E.; Kutys, R.; Skorija, K.; Gold, H.; Virmani, R. Pathology of drugeluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol., 2006, 48, 193.
22. Lanzer, P.; Sternberg, K.; Schmitz, K.; Kolodgie, F.; Nakazawa, G.; Virmani, R. Drug-eluting coronary stent very late thrombosis revisited. Herz, 2008, 33, 334.
23. Nebeker, J.; Virmani, R.; Bennett, C.; Hoffman, J.; Samore, M.; Alvarez, J.; Davidson, C.; McKoy, J.; Raisch, D.; Whisenant, B.; Yarnold, P.; Belknap, S.; West, D.; Gage, J.; Morse, R.; Gligoric, G.; Davidson, L.; Feldman, M. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol., 2006, 47, 175.
24. Virmani, R.; Kolodgie, F.; Farb, A. Drug-eluting stents: are they really safe? Am. Heart Hosp. J., 2004, 2, 85.
25. Meredith, I.; Ormiston, J.; Whitbourn, R.; Kay, I.; Muller, D.; Bonan, R.; Popma, J.; Cutlip, D.; Fitzgerald, P.; Prpic, R.; Kuntz, R. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention, 2005, 1, 157.
26. Kandzari, D.; Leon, M.; Popma, J.; Fitzgerald, P.; O'Shaughnessy, C.; Ball, M.; Turco, M.; Applegate, R.; Gurbel, P.; Midei, M.; Badre, S.; Mauri, L.; Thompson, K.; LeNarz, L.; Kuntz, R. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol., 2006, 48, 2440.
27. Fajadet, J.; Wijns, W.; Laarman, G.; Kuck, K.; Ormiston, J.; Münzel, T.; Popma, J.; Fitzgerald, P.; Bonan, R.; Kuntz, R. Randomized, double-blind, multicenter study of the Endeavor zotarolimuselutig phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation, 2006, 22, 798.
28. Miyazawa, A.; Ako, J.; Hongo, Y.; Hur, S.; Tsujino, I.; Courtney, B.; Hassan, A.; Kandzari, D.; Honda, Y.; Fitzgerald, P. Comparison of vascular response to zotarolimus-eluting stent versus sirolimuseluting stent: intravascular ultrasound results from ENDEAVOR III. Am. Heart J., 2008, 155, 101.
29. Schuler, W.; Sedrani, R.; Cottens, S.; Häberlin, B.; Schulz, M.; Schuurman, H.J. Zenke, G.; Zerwes, H.; Schreier, M. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation, 1997, 64, 36.
30. Grube, E.; Sonoda, S.; Ikeno, F.; Honda, Y.; Kar, S.; Chan, C.; Gerckens, U.; Lansky, A.; Fitzgerald, P. Six-and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation, 2004, 109, 2168.
31. Serruys, P.; Ong, A.; Piek, J.; Neumann, F.; van der Giessen, W.; Wiemer, M.; Zeiher, A.; Grube, E.; Haase, J.; Thuesen, L.; Hamm, C.; Otto-Terlouw, P. A randomized comparison of a durable poly mer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention, 2005, 1, 58.
32. Grube, E.; Buellesfeld, L.; Neumann, F.; Verheye, S.; Abizaid, A.; McClean, D.; Mueller, R.; Lansky, A.; Mehran, R.; Costa, R.; Gerckens, U.; Trauthen, B.; Fitzgerald, P. Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. Am. J. Cardiol., 2007, 99, 1691.
33. Grube, E.; Buellesfeld, L. Rapamycin analogs for stent-based local drug delivery. Everolimus-and tacrolimus-eluting stents. Herz, 2004, 29, 162.
34. Matter, C.; Rozenberg, I.; Jaschko, A.; Greutert, H.; Kurz, D.; Wnendt, S.; Kuttler, B.; Joch, H.; Grünenfelder, J.; Zünd, G.; Tanner, F.; Lüscher, T. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J. Cardiovasc. Pharmacol., 2006, 48, 286.
35. Onuma, Y.; Serruys, P.; den Heijer, P.; Joesoef, K.; Duckers, H.; Regar, E.; Kukreja, N.; Tanimoto, S.; Garcia-Garcia, H.; van Beusekom, H.; van der Giessen, W.; Nishide, T. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. Eur. Heart J., 2009, 30, 1477.
36. Verheye, S.; Sarno, G.; Müller, R.; Birkemeyer, R.; Vrints, C.; Jung, W.; Agostoni, P.; van Langenhove, G.; Haine, S.; Willems, T.; Haude, M.; Grube, E.; Wijns, W. The ProLimus trial: a prospective, non-randomised, multicentre trial to evaluate the safety and clinical performance of the pimecrolimus eluting stent system (ProGenic). EuroIntervention, 2009, 5, 233.
37. Ormiston, J.; Webster, M.; Schwartz, R.; Gladding, P.; Stewart, J.; Kay, I.; Ruygrok, P.; Hatrick, R. Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional preclinical safety end points failed to predict 6-month clinical angiographic results. J. Am. Coll. Cardiol. Cardiovasc. Interv., 2009, 2, 1017.
38. Verheye, S.; Agostoni, P.; Dawkins, K.; Dens, J.; Rutsch, W.; Carrie, D.; Schofer, J.; Lotan, C.; Dubois, C.; Cohen, S.; Fitzgerald, P.; Lansky, A. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial. J. Am. Coll. Cardiol. Cardiovasc. Interv., 2009, 2, 205.
39. Adriaenssens, T.; Mehilli, J.; Wessely, R.; Ndrepepa, G.; Seyfarth, M.; Wieczorek, A.; Blaich, B.; Iijima, R.; Pache, J.; Kastrati, A.; Schömig, A. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J. Am. Coll. Cardiol., 2007, 49, 1265.
40. Byrne, R.; Kastrati, A.; Kufner, S.; Massberg, S.; Birkmeier, K.; Laugwitz, K.; Schulz, S.; Pache, J.; Fusaro, M.; Seyfarth, M.; Schömig, A.; Mehilli, J. Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur. Heart J., 2009, 30, 2441.
41. Huang, Y.; Venkatraman, S.; Boey, F.; Lahti, E.; Umashankar, P.; Mohanty, M.; Arumugam, S.; Khanolkar, L.; Vaishnav, S. In vitro and in vivo performance of a dual drug-eluting stent (DDES). Biomaterials, 2010, 31, 4382.
42. Leon, M.; Kandzari, D.; Eisenstein, E.; Anstrom, K.; Mauri, L.; Cutlip, D.; Nikolsky, E.; O'Shaughnessy, C.; Overlie, P.; Kirtane, A.; McLaurin, B.; Solomon, S.; Douglas, J.; Popma, J. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). J. Am. Coll. Cardiol., 2009, 2, 1208.
43. Bünger, C.; Grabow, N.; Kröger, C.; Lorenzen, B.; Hauenstein, K.; Goosmann, M.; Schmitz, K.; Kreutzer, H.; Lootz, D.; Ince, H.; Nienaber, C.; Klar, E.; Schareck, W.; Sternberg, K. Iliac anastomotic stenting with a sirolimus-eluting biodegradable poly-Llactide stent: a preliminary study after 6 weeks. J. Endovasc. Ther., 2006, 13, 630.
44. Sternberg, K.; Kramer, S.; Nischan, C.; Grabow, N.; Langer, T.; Hennighausen, G.; Schmitz, K. In vitro study of drug-eluting stent coatings based on poly(L-lactide) incorporating cyclosporine A-drug release, polymer degradation and mechanical integrity. J. Mater. Sci.: Mater. Med, 2007, 18(7), 1423.
45. Ge, J.; Qian, J.; Wang, X.; Wang, Q.; Yan, W.; Yan, Y.; Fan, B.; Ge, L.; Liu, X. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries. Catheter. Cardio. Interv., 2007, 69, 198.
46. Pan, C.; Tang, J.; Weng, Y.; Wang, J.; Huang, N. Preparation and characterization of rapamycin-loaded PLGA coating stent. J. Mater. Sci.: Mater. Med., 2007, 18, 2193.
47. Grabow, N.; Martin, D.; Schmitz, K.; Sternberg, K. Absorbable polymer stent technologies for vascular regeneration. J. Chem. Technol. Biotechnol., 2010, 85, 744.
48. Freier, T.; Kunze, C.; Nischan, C.; Kramer, S.; Sternberg, K.; Sass, M.; Hopt, U.; Schmitz, K. In vitro and in vivo degradation studies for development of a biodegradable patch based on poly(3-hydroxybutyrate). Biomaterials, 2002, 23, 2649.
49. Wang, X.; Venkatraman, S.; Boey, F.; Loo, J.; Tan, L. Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials, 2006, 27, 5588.
50. Costantini, C.; Londero, H.; De Scheeder, I.; Tarbine, S.; Costantini, C.; Cabrera, M.; Santos, M.; Darwich, R.; Maranhao, M.; Bubna, M.; Andrade, M.; Yared, A. Final results and two years outcomes of a trial assessing a nitric oxide preserver polymercoated stent implantation in de novo coronary lesions: Clinical, angiographic, and stent volumetric analysis from NOBLESSE trial. Am. J. Cardiol., 2005, 96(Suppl. S), 39H.
51. DeFife, K.; Grako, K.; Cruz-Aranda, G.; Price, S.; Chantung, R.; Macpherson, K.; Khoshabeh, R.; Gopalan, S.; Turnell, W. Copolymers Promote Blood and Tissue Compatibility. J. Biomater. Sci. Polym. Ed., 2009, 20, 1495.
52. Grube, E.; Buellesfeld, L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Exp. Rev. Med. Dev., 2006, 3, 731.
53. Chevalier, B.; Silber, S.; Park, S.; Garcia, E.; Schuler, G.; Suryapranata, H.; Koolen, J.; Hauptmann, K.; Wijns, W.; Morice, M.; Carrie, D.; van Es, G.; Nagai, H.; Detiege, D.; Paunovic, D.; Serruys, P. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial-Phase 2. Circulation Cardio. Interv., 2009, 2, 188.
54. Ruef, J.; Störger, H.; Schwarz, F.; Haase, J. Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. Catheter. Cardio. Interv., 2008, 71, 333.
55. Chai, F.; Ochsenbein, A.; Traisnel, M.; Busch, R.; Breme, J.; Hildebrand, H. Improving endothelial cell adhesion and proliferation on titanium by sol-gel derived oxide coating. J. Biomed. Mater. Res. A, 2010, 92, 754.
56. Kollum, M.; Farb, A.; Schreiber, R.; Terfera, K.; Arab, A.; Geist, A.; Haberstroh, J.; Wnendt, S.; Virmani, R.; Hehrlein, C. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter. Cardio. Interv., 2005, 64, 85.
57. Chorny, M.; Fishbein, I.; Yellen, B.; Alferiev, I.; Bakay, M.; Ganta, S.; Adamo, R.; Amiji, M.; Friedman, G.; Levy, R. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. PNAS, 2010, 107, 8346.
58. Bhargava, B.; Reddy, N.; Karthikeyan, G.; Raju, R.; Mishra, S.; Singh, S.; Waksman, R.; Virmani, R.; Somaraju, B., A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model, Catheter. Cardio. Interv., 2006, 67, 698.
59. Margolis, J.; McDonald, J.; Heuser, R.; Klinke, P.; Waksman, R.; Virmani, R.; Desai, N.; Hilton, D. Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-inhuman safety and dose-finding study. Clin. Cardiol., 2007, 30, 165.
60. Luderer, F.; Löbler, M.; Rohm, H.; Gocke, C.; Kunna, K.; Kock, K.; Kroemer, H.; Weitschies, W.; Schmitz, K.; Sternberg, K. Biodegradable Sirolimus-loaded Poly(lactide) Nanoparticles as Drug Delivery System for the Prevention of In-Stent Restenosis in Coro nary Stent Application. J. Biomater Appl., 2010, Electronic publication ahead of print.
61. Jordan, S.; Chaikof, E. Novel thromboresistant materials. J. Vasc. Surg., 2007, 45, A104.
62. Serruys, P.; Emanuelsson, H.; van der Giessen, W.; Lunn, A.; Kiemeney, F.; Macaya, C.; Rutsch, W.; Heyndrick, G.; Suryapranata, H.; Legrand, V.; Goy, J.; Materne, P.; Bonnier, H.; Morice, M.; Fajadet, J.; Belardi, J.; Colombo, A.; Garcia, E.; Ruygrok, P.; de Jaegere, P.; Morel, M. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation, 1996, 93, 412.
63. Serruys, P.; Van Hout, B.; Bonnier, H.; Legrand, V.; Garcia, E.; Macaya, C.; Sousa, E.; van der Giessen, W.; Colombo, A.; Seabra-Gomes, R.; Kiemeneij, F.; Ruygrok, P.; Ormiston, J.; Emanuelsson, H.; Fajadet, J.; Haude, M.; Klugmann, S.; Morel, M. Randomized comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). The Lancet, 1998, 352, 673.
64. Vrolix, M.; Legrand, V.; Reiber, J.; Grollier, G.; Schalij, M.; Brunel, P.; Martinez-Elbal, L.; Gomez-Recio, M.; Bär, F.; Bertrand, M.; Colombo, A.; Brachman, J. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). Am. J. Cardiol., 2000, 86, 385.
65. Wöhrle, J.; Al-Khayer, E.; Grötzinger, U.; Schindler, C.; Kochs, M.K.; Hombach, V.; Höher, M. Comparison of the heparin coated vs the uncoated Jostent-no influence on restenosis or clinical outcome. Eur. Heart J., 2001, 22, 1808.
66. Kipshidize, N.; Baker, J.; Nikolaychik, N. Fibrin-coated stents as an improved vehicle for endothelial cell seeding. Circulation, 1994, 90, I-592.
67. Holmes, D.; Camrud, A.; Jorgenson, M.; Edwards, W.; Schwartz, R. Polymeric stenting in the porcine coronary artery model: differential outcome of exogeneous fibrin sleeves versus polyurethanecoated stents. J. Am. Coll. Cardiol., 1994, 24, 525.
68. Aggarwal, R.; Ireland, D.; Azrin, M.; de Bono, D.; Gershlik, A. Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIa receptor antibody. Circulation, 1996, 94, 3311.
69. Cox, D.; Anderson, P.; Roubin, G. anc Chou, C.; Agrawal, S.; Cavender, J. Effects of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries. Coronary Artery Dis., 1992, 3, 237.
70. Hayward, J.; Chapman, D. Biomembrane surfaces as models for polymer design: The potential for haemocompatibility. Biomaterials, 1984, 5, 135.
71. Lewis, A.; Stratford, P. Phosphorylcholine-coated stents. J. Long Term Eff. Med. Implants, 2002, 12, 231.
72. Boland, J. L amd Corbeij, H.; van der Giessen, W.; Seabra-Gomes, R.; Suryapranata, H.; Wijns, W.; Hanet, C.; Suttorp, M.; Buller, C.; Bonnier, J.; Colombo, A.; van Birgelen, C.; M Pieper, M.; Mangioni, J.; Londero, H.; Carere, R.; Hamm, C.; Bonan, R.; Bartorelli, A.; Kyriakides, Z.; Chauhan, A.; Rothman, M.; Grinfeld, L.; Oosterwijk, C.; Serruys, P.; Cumberland, D. Multicenter evaluation of the phosphorylcholine coated biodivYsio stent in short de novo coronary lesions: The SOPHOS study. Int. J. Cardiovasc. Interv., 2000, 3, 215.
73. Dichek, D.; Neville, R.; Zwiebel, J.; Freeman, S.; Leon, M.; Anderson, W. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation, 1989, 80, 1347.
74. Flugelman, M.; Virmani, R.; Leon, M.; Bowman, R.; Dichek, D. Genetically engineered endothelial cells remain adherent and viable after stent deployment and exposure to flow in vitro. Circulation, 1992, 70, 348.
75. Shirota, T.; Yasui, H.; Shimokawa, H.; Matsuda, T. Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue. Biomaterials, 2003, 24, 2295.
76. Ong, A.; Aoki, J.; Kutryk, M.; Serruys, P. How to accelerate the endothelialization of stents. Arch. Mal. Coeur Vaiss., 2005, 98, 123.
77. Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der Zee, R.; Li, T. Witzenbichler, B.; Schatteman, G.; Isner, J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science, 1997, 275, 964.
78. Hristov, M.; Erl, W.; Weber, P. Endothelial progenitor cells: mobilization, differentiation and homing. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 1185.
79. Stello, K.; Gawaz, M. Platelets and stromal cell-derived factor-1 in progenitor cell recruitment. Semin. Thromb. Hemost., 2007, 33, 159.
80. Yin, Y.; Zhao, X.; Fang, Y.; Yu, S.; Zhao, J.; Song, M.; Huang, L. SDF-1alpha involved in mobilization and recruitment of endothelial progenitor cells after arterial injury in mice. Cardiovasc. Pathol., 2009, 19, 218.
81. Asahara, T.; Takahashi, T.; Masuda, H.; Kalka, C.; Chen, D.; Iwaguro, H.; Inai, Y.; Silver, M.; Isner, J. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J., 1999, 18, 3964.
82. Honold, J.; Lehmann, R.; Heeschen, C.; Walter, D.; Assmus, B.; Sasaki, K.; Martin, H.; Haendeler, J.; Zeiher, A.M.; Dimmeler, S. Effects of granulocyte colony stimulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2238.
83. Körbling, M.; Reuben, J.M.; Gao, H.; Lee, B.; Harris, D.M.; Cogdell, D.; Giralt, S.; Khouri, I.; Saliba, R.; Champlin, R.; Zhang, W.; Estrov, Z. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion, 2006, 46, 1795.
84. Aoki, J.; Serruys, P.W.; van Beusekom, H.; Ong, A.T.; McFadden, E.P.; Sianos, G.; van der Giessen, W.J.; Regar, E.; de Feyter, P.J.; Davis, H.R.; Rowland, S.; Kutryk, M.J. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J. Am. Coll. Cardiol., 2005, 45, 574.
85. Duckers, H.; Silber, S.; de Winter, R.; den Heijer, P.; B., R.; Rau, M.; Mudra, H.; Benit, E.; Verheye, S.; Wijns, W.; Serruys, P. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. EuroIntervention, 2007, 3, 67.
86. Duckers, H.; Soullie, T.; den heijer, P.; Rensing, B.; de Winter, R.; Rau, M.; Mudra, H. Silber, S.; Benit, E.; Verheye, S.; Wijns, W.; Serruys, P. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the HEALING II trial using endothelial progenitor cell capturing stent (Geneous R stent). EuroIntervention, 2007, 3, 350.
87. Duckers, H.; Onuma, Y.; Benit, E.; de Winter, R.; Wijns, W.; Grisold, M.; Verheye, S.; Silber, S.; Teiger, E.; Hill, J.; Serruys, P. Final results of the HEALING 2B trial to evaluate a bioengineered CD34 antibody coated stent (Geneous stent) designed to promote vascular healing by capture of circulating endothelial progenitor cell in CAD patients. Circulation, 2008, 118, S1042.
88. Miglionico, M.; Patti, G.; D'Ambrosio, A.; Di Sciascio, G. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients. Catheter. Cardiovasc. Interv., 2008, 71, 600.
89. Cervinka, P. Randomized comparison of Geneous stent vs chromium-cobalt stent for treatment of ST-elevation myocardial infarction. A 6-month clinical, angiographic abd IVUS follow-up. GENIUS STEMI Trial. i2 Summit at the American College of Cardiology Scientific Sessions 29-31 March 2009 Orlando, Florida, USA.
90. Meredith, I.; Worthley, S.; R., W.; Walters, D.; Popma, J.; Cutlip, D.; Fitzgerald, P. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention, 2007, 3, 50.
91. Windecker, S.; Serruys, P.; Wandel, S.; Buszman, P.; Trznadel, S.; Linke, A.; Len, K.; Ischinger, T.; Klauss, V.; Eberli, F.; Corti, R.; Wijns, W.; Morice, M.; die Mario, C.; Davies, S.; van Geuns, R.; Eerdmans, P.; van Es, G.; Meier, B.; Juni, P., Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting setnt with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial, The Lancet, 2008, 372, 1163.
92. Peichev, M.; Naiyer, A.J.N.; Pereira, D.; Zhu, Z.; Lane, W.J.; Williams, M.; Oz, M.C.; Hicklin, D.J.; Witte, L.; Moore, M.A.S.; Rafii, S. Expression of VEGFR-2 and AC133 by circulating human CD34 cells identifies a population of functional endothelial precursor. Blood, 2000, 95, 952.
93. Markway, B.D.; McCarty, O.J.; Marzec, U.M.; Courtman, D.W.; Hanson, S.R.; Hinds, M.T. Capture of flowing endothelial cells using surface-immobilized anti-kinase insert domain receptor antibody. Tissue Eng. Part C, 2008, 14, 97.
94. Ellington, A.; Szostak, J. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346, 818.
95. Hoffmann, J.; Paul, A.; Harwardt, M.; Groll, J.; Reeswinkel, T.; Klee, D.; Moeller, M.; Fischer, H.; Walker, T.; Greiner, T.; Ziemer, G.; Wendel, H.P. Immobilized DNA aptamers used as potent attractors for porcine endothelial precursor cells. J. Biomed. Mater. Res. A, 2008, pages 614.
96. Blindt, R.; Vogt, F.; Astafieva, I.; Fach, C.; Hristov, M.; Krott, N.; Seitz, B.; Kapurniotu, A.; Kwok, C.; Dewor, M.; Bosserhoff, A.K.; Bernhagen, J.; Hanrath, P.H.; Hoffmann, R.; Weber, C. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J. Am. Coll. Cardiol., 2006, 47, 1787.
97. Taite, L.J.; Yang, P.; Jun, H.W.; West, J.L. Nitric oxide-releasing polyurethane-PEG copolymer containing the YIGSR peptide promotes endothelialization with decreased platelet adhesion. J. Biomed. Mater. Res. Part B, 2007, 108.
98. Veleva, A.N.; Heath, D.E.; Cooper, S.L.; Patterson, C. Selective endothelial cell attachment to peptide-modified terpolymers. Biomaterials, 2008, 29, 3656.
99. Nakazawa, G.; Granada, J.; Alviar, C.; Tellez, A.; Kaluza, G.; Guilhermier, M.; Parker, S.; Rowland, S.; Kolodgie, F.; Leon, M.; Virmani, R. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. J. Am. Coll. Cardiol., 2010, 3, 68.
100. Granada, J. The Orbus-Neich EPC-coated bioabsorbable polymer sirolimus-eluting stent program. Presentation at Transcatheter Therapeutics, San Francisco, 21st September 2009.
101. Zidar, J. Textbook of Interventional Cardiology, 787-802, WB Saunders: Philadelphia, 1994.
102. Colombo, A.; Karvouni, E. Biodegradable stents: "fulfilling the mission and stepping away". Circulation, 2000, 102, 371.
103. Erne, P.; Schier, M.; Resink, T. The road to bioabsorbable stents: Reaching clinical reality? Cardiovasc. Intervent. Radiol., 2005, 29, 11.
104. Zilberman, M.; Eberhart, R. Drug-eluting bioresorbable stents for various applications. Annu. Rev. Biomed. Eng., 2006, 8, 153.
105. Sharkawi, T.; Cornhill, F.; Lafont, A.; Sabaria, P.; Vert, M. Intravascular bioresorbable polymeric stents: a potential alternative to current drug eluting metal stents. J. Pharm. Sci., 2007, 96, 2829.
106. Brown, D.; Lee, E.; Loh, C.; Kee, S. A new wave in treatment of vascular occlusive disease: biodegradable stents-clinical experience and scientific principles. J. Vasc. Interv. Radiol., 2009, 20(3), 315.
107. Zartner, P.; Buettner, M.; Singer, H.; Sigler, M. First biodegradable metal stent in a child with congenital heart disease: evaluation of macro and histopathology. Catheter. Cardiovasc. Interv, 2007, 69(3), 443.
108. Siersema, P. Stenting for benign esophageal strictures. Endoscopy, 2009, 41(4), 363.
109. Petrtyl, J.; Bruha, R.; Horak, L.; Zadorova, Z.; Dosedel, J.; Laasch, H. Management of benign intrahepatic bile duct strictures: initial experience with polydioxanone biodegradable stents. Endoscopy, 2010, 42 (Suppl 2), E89.
110. Laukkarinen, J.; Sand, J.; Chow, P.; Juuti, H.; Kellomaki, M.; Karkkainen, P.; Isola, J.; Yu, S.; Somanesan, S.; Kee, I.; Song, I.; Ng, T.; Nordback, I. A novel biodegradable biliary stent in the normal duct hepaticojejunal anastomosis: an 18-month follow-up in a large animal model. J. Gastrointest. Surg., 2007, 11(6), 750.
111. Sternberg, K.; Selent, C.; Hakansson, N.; Tollner, J.; Langer, T.; Seiter, H.; Schmitz, K. Bioartificial materials in urology. Urologe A, 2004, 43(10), 1200.
112. Kotsar, A.; Isotalo, T.; Uurto, I.; Mikkonen, J.; Martikainen, P.; Talja, M.; Kellomaki, M.; Salenius, J.; Tammela, T. Urethral in situ biocompatibility of new drug-eluting biodegradable stents: an experimental study in the rabbit. BJU Int, 2009, 103(8), 1132.
113. Stack, R.; Califf, R.; Phillips, H.; Pryor, D.; Quigley, P.; Bauman, R.; Tcheng, J.; Greenfield, J.C. Interventional cardiac catheterization at Duke Medical Center. Am. J. Cardiol., 1988, 62, 3F.
114. Uurto, I.; Juuti, H.; Parkkinen, J.; Kellomaki, M.; Keski-Nisula, L.; Nevalainen, T.; Tormala, P.; Salenius, J. Biodegradable selfexpanding poly-L/D-lactic acid vascular stent: a pilot study in canine and porcine iliac arteries. J. Endovasc. Ther., 2004, 11, 712.
115. Venkatraman, S.; Tan, L.; Joso, J.; Boey, Y.; Wang, X. Biodegradable stents with elastic memory. Biomaterials, 2006, 27, 1573.
116. Wong, Y.; Xiong, Y.; Venkatraman, S.; Boey, F. Shape memory in un-cross-linked biodegradable polymers. J. Biomater. Sci. Polym. Ed., 2008, 19, 175.
117. Venkatraman, S.; Poh, T.; Vinalia, T.; Mak, K.; Boey, F. Collapse pressures of biodegradable stents. Biomaterials, 2003, 24, 2105.
118. Zilberman, M.; Nelson, K.; Eberhart, R. Mechanical properties and in vitro degradation of bioresorbable fibers and expandable fiberbased stents. J. Biomed. Mater. Res. Part B, 2005, 74, 792.
119. Welch, T.; Eberhart, R.; Chuong, C. The influence of thermal treatment on the mechanical characteristics of a PLLA coiled stent. J. Biomed. Mater. Res. Part B, 2009, 90, 302.
120. Tsuji, T.; Tamai, H.; Igaki, K.; Kyo, E.; Kosuga, K.; Hata, T.; Nakamura, T.; Fujita, S.; Takeda, S.; Motohara, S.; Uehata, H. Biodegradable stents as a platform to drug loading. Int. J. Cardiovasc. Intervent., 2003, 5, 13.
121. Alexis, F.; Venkatraman, S.; Rath, S.; Boey, F. In vitro study of release mechanisms of paclitaxel and rapamycin from drugincorporated biodegradable stent matrices. J. Control. Release, 2004, 98, 67.
122. Vogt, F.; Stein, A.; Rettemeier, G.; Krott, N.; Hoffmann, R.; vom Dahl, J.; Bosserhoff, A.; Michaeli, W.; Hanrath, P.; Weber, C.; Blindt, R. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur. Heart J., 2004, 25, 1330.
123. Uurto, I.; Mikkonen, J.; Parkkinen, J.; Keski-Nisula, L.; Nevalainen, T.; Kellomaki, M.; Tormala, P.; Salenius, J. Drug-eluting biodegradable poly-D/L-lactic acid vascular stents: an experimental pilot study. J. Endovasc. Ther., 2005, 12, 371.
124. Mikkonen, J.; Uurto, I.; Isotalo, T.; Kotsar, A.; Tammela, T.; Talja, M.; Salenius, J.; Tormala, P.; Kellomaki, M. Drug-eluting bioabsorbable stents-an in vitro study. Acta Biomater., 2009, 5(8), 2894.
125. Grabow, N.; Schlun, M.; Sternberg, K.; Hakansson, N.; Kramer, S.; Schmitz, K. Mechanical properties of laser cut poly(L-lactide) micro-specimens: implications for stent design, manufacture, and sterilization. ASME J. Biomech. Eng., 2005, 127, 25.
126. Grabow, N.; Bunger, C.; Sternberg, K.; Mews, S.; Schmohl, K.; Schmitz, K. Mechanical properties of a biodegradable balloonexpandable stent from poly(L-lactide) for peripheral vascular applications. ASME J. Med. Devices, 2007, 1, 84.
127. Schwartz, R.S.; Edelman, Elazer R.; Carter, A.; Chronos, N.; Rogers, C.; Robinson, K.A.; Waksman, R.; Weinberger, J.; Wilensky, R.L.; Jensen, D.N.; Zuckerman, B.D.; Virmani, R. Drugeluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation, 2002, 106, 1867.
128. Bünger, C.; Grabow, N.; Sternberg, K.; Goosmann, M.; Schmitz, K.; Kreutzer, H.; Ince, H.; Klische, S.; Nienaber, C.; Martin, D.; Williams, S.; Klar, E.; Schareck, W. A biodegradable stent based on poly(L-lactide) and poly(4-hydroxybutyrate) for peripheral vascular application: Preliminary experience in the pig. J. Endovasc. Ther., 2007, 14, 725.
129. Hori, Y.; Yamaguchi, A.; Hagiwara, T. Chemical synthesis of high molecular weight poly(3-hydroxybutyrate-co-4-hydroxybutyrate). Polymer, 1995, 36, 4703.
130. Martin, D.; Williams, D. Medical applications of poly-4-hydroxybutyrate: a strong flexible absorbable material. Biochem. Eng. J., 2003, 16, 97.
131. Tamai, H.; Igaki, K.; Kyo, E.; Kosuga, K.; Kawashima, A.; Matsui, S.; Komori, H.; Tsuji, T.; Motohara, S.; Uehata, H. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation, 2000, 102, 399.
132. Tsuji, T.; Tamai, H.; Igaki, K.; Kyo, E.; Kosuga, K.; Okada, M.; Nakamura, T.; Fujita, S.; Takeda, S.; Motohara, S.; Uehata, H. The influence of biodegradation of the biodegradable stent on vessel in long-term period: Serial intravascular ultrasound analysis of the Igaki-Tamai biodegradable stent. Circulation, 2002, 106, 356.
133. Biamino, G.; Schmidt, A.; Scheinert, D. Treatment of SFA lesions with PLLA biodegradable stents: results of the PERSEUS study. J. Endovasc. Ther., 2005, 12 (Suppl-I-5).
134. Ormiston, J.; Webster, M.; Armstrong, G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: The BVS poly-Llactic acid everolimus-eluting coronary stent. Catheter. Cardiovasc. Interv., 2006, 69, 128.
135. Serruys, P.; Ormiston, J.; Onuma, Y.; Regar, E.; Gonzalo, N.; Garcia-Garcia, H.; Nieman, K.; Bruining, N.; Dorange, C.; Miquel-Hebert, K.; Veldhof, S.; Webster, M.; Thuesen, L.; Dudek, D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. The Lancet, 2009, 373, 897.
136. Bruining, N.; de Winter, S.; Roelandt, J.; Regar, E.; Heller, I.; van Domburg, R.; Hamers, R.; Onuma, Y.; Dudek, D.; Webster, M.; Thuesen, L.; Ormiston, J.; Cheong, W.; Miquel-Hebert, K.; Veldhof, S.; Serruys, P. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study. JACC Cardiovasc. Interv., 2010, 3(4), 449.
137. Kohn, J.; Zeltinger, J. Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease. Expert Rev. Med. Devices, 2005, 2, 667.
138. Peuster, M.; Wohlsein, P.; Brugmann, M.; Ehlerding, M.; Seidler, K.; Fink, C.; Brauer, H.; Fischer, A.; Hausdorf, G. A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits. Heart, 2001, 86, 563.
139. Peuster, M.; Hesse, C.; Schloo, T.; Fink, C.; Beerbaum, P.; von Schnakenburg, C. Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. Biomaterials, 2006, 27(28), 4955.
140. Di Mario, C.; Griffiths, H.; Goktekin, O.; Peeters, N.; Verbist, J.; Bosiers, M.; Deloose, K.; Heublein, B.; Rohde, R.; Kasese, V.; Ilsley, C.; Erbel, R. Drug-eluting bioabsorbable magnesium stent. J. Interv. Cardiol., 2004, 17, 391.
141. Erbel, R.; Di Mario, C.; Bartunek, J.; Bonnier, J.; de Bruyne, B.; Eberli, F.; Erne, P.; Haude, M.; Heublein, B.; Horrigan, M.; Ilsley, C.; Bose, D.; Koolen, J.; Luscher, T.; Weissman, N.; Waksman, R. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. The Lancet, 2007, 369, 1869.
142. Waksman, R.; Erbel, R.; Di Mario, C.; Bartunek, J.; de Bruyne, B.; Eberli, F.; Erne, P.; Haude, M.; Horrigan, M.; Ilsley, C.; Bose, D.; Bonnier, H.; Koolen, J.; Luscher, T.; Weissman, N. Early-and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. J. Am. Coll. Cardiol. Cardiovasc. Interv., 2009, 2, 312.
143. Schmidt, W.; Lanzer, P.; Behrens, P.; Topoleski, L.; Schmitz, K. A comparison of the mechanical performance characteristics of seven drug-eluting stent systems. Catheter. Cardiovasc. Interv., 2009, 73(3), 350.
144. Wykrzykowska, J.; Onuma, Y.; Serruys, P. Advances in stent drug delivery: the future is in bioabsorbable stents. Expert Opin. Drug Deliv., 2009, 6(2), 113.